Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Molecular Cancer Therapeutics
J Ma, David J Waxman

Abstract

The promising but still limited efficacy of angiogenesis inhibitors as monotherapies for cancer treatment indicates a need to integrate these agents into existing therapeutic regimens. Presently, we investigate the antitumor activity of the small-molecule angiogenesis inhibitor axitinib (AG-013736) and its potential for combination with metronomic cyclophosphamide. Axitinib significantly inhibited angiogenesis in rat 9L tumors grown s.c. in scid mice but only moderately delayed tumor growth. Combination of axitinib with metronomic cyclophosphamide fully blocked 9L tumor growth on initiation of drug treatment. In contrast, metronomic cyclophosphamide alone required multiple treatment cycles to halt tumor growth. However, in contrast to the substantial tumor regression that is ultimately induced by metronomic cyclophosphamide, the axitinib/cyclophosphamide combination was tumor growth static. Axitinib did not inhibit hepatic activation of cyclophosphamide or export of its activated metabolite, 4-hydroxy-cyclophosphamide (4-OH-CPA), to extrahepatic tissues; rather, axitinib selectively decreased 9L tumor uptake of 4-OH-CPA by 30% to 40%. The reduced tumor penetration of 4-OH-CPA was associated with a decrease in cyclophosphamide-i...Continue Reading

References

Apr 20, 2000·The Journal of Clinical Investigation·D HanahanE Bergsland
Nov 28, 2001·Molecular Pharmacology·P S Schwartz, D J Waxman
Jun 12, 2003·British Journal of Cancer·H WildiersA T van Oosterom
Oct 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Guido BocciRobert S Kerbel
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Nov 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristian Pietras, Douglas Hanahan
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Sep 21, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Tomomi KambaDonald M McDonald
Oct 19, 2005·Neoplasia : an International Journal for Oncology Research·Wilfried ReichardtAlexei Bogdanov
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
Jan 13, 2006·Nature Clinical Practice. Oncology·Rakesh K JainJay S Loeffler
May 23, 2006·Cancer Treatment Reviews·Carsten NiederMichael Molls
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masahisa Jinushi, Glenn Dranoff
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paxton V DicksonAndrew M Davidoff

❮ Previous
Next ❯

Citations

Apr 8, 2010·Pharmaceutical Research·Andrei Ponta, Younsoo Bae
Aug 1, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·José L OrgazBenilde Jiménez
Mar 18, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hollie I SwansonEmily E Scott
Nov 30, 2012·The Journal of Pharmacology and Experimental Therapeutics·Eugene Manley, David J Waxman
Mar 31, 2011·Cancer Research·Jie MaDavid J Waxman
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jie Ma, David J Waxman
Jul 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sushil KumarSylvain Baruchel
Dec 17, 2008·Molecular Cancer Therapeutics·Jie Ma, David J Waxman
Mar 30, 2010·Journal of Cancer Research and Clinical Oncology·Leandro E MainettiO Graciela Scharovsky
Oct 15, 2010·Expert Review of Anticancer Therapy·Robert GoldsteinJames Larkin
Aug 26, 2010·Expert Review of Anticancer Therapy·Iyad Sultan, Andrea Ferrari
Jun 25, 2009·Expert Opinion on Investigational Drugs·David P SamuelMark W Kieran
Feb 7, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jair Bar, Glenwood D Goss
Mar 8, 2013·Biomaterials·De-Hong YuHong-Zhuan Chen
Feb 25, 2014·Neoplasia : an International Journal for Oncology Research·Chong-Sheng ChenDavid J Waxman
Jun 18, 2014·Journal of Medicinal Chemistry·Paul M LevineKent Kirshenbaum
Aug 22, 2009·European Journal of Pharmacology·Anna FioravantiGuido Bocci
Mar 12, 2015·Scientific Reports·Andrea WeissPatrycja Nowak-Sliwinska
Sep 11, 2018·ChemMedChem·Dorian SchmidtChristian Peifer
Nov 9, 2019·Tumori·Andrea FerrariMichela Casanova
Aug 16, 2013·Oncology Letters·Xiao-Hua ZhangYan-Hong Gu
Aug 14, 2021·Advanced Drug Delivery Reviews·Victoria LaiJoshua C Doloff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.